ERBB2 and cancer: While ErbB2 inhibitors such as lapatinib and neratinib are approved and well characterized for cancer therapy, their blood–brain barrier permeability and neuronal specificity remain limited [47,48], raising concerns about off-target effects on glial and neuronal viability.